

APPROVED FOR RELEASE



CONTRACT RESEARCH AGREEMENT WITH SK LIFE SCIENCE

PGXL to Provide Genetic Profiles for Clinical Research

PGXL has signed an agreement to provide laboratory services for SK Life Science, Inc. PGXL will perform genotype analysis to be used in identifying subjects for upcoming clinical trials.

“As genetic analysis becomes more and more a part of drug development,” says Dr. Roland Valdes, Jr., Chairman of PGXL, “the need to identify large numbers of subjects fitting a specific genetic profile grows. We’re forming partnerships with pharmaceutical and contract research organizations that need this type of genotyping done quickly and accurately.”

About SK Life Science

SK Life Science, Inc., is an American subsidiary of SK Biopharmaceuticals Co., Ltd., which is one of the companies of SK Group, South Korea’s third-largest conglomerate. SK Life Science is responsible for the global clinical trials of new drugs and marketing of pharmaceutical intermediates and APIs.

About PGXL Laboratories:

A privately-owned business located in Louisville, Kentucky, PGXL Laboratories was the first lab in the country CLIA-certified specifically to conduct pharmacogenetic tests. It offers pharmacogenetic testing and interpretive services, and developed one of the first commercial CYP2C9/VKORC1 tests for accurate anticoagulant dosing. Along with its clinical practice, PGXL performs contract research for manufacturers of pharmaceuticals and medical equipment.

CONTACT:

Tom Johnson

Director of Communications

502-419-8204

Tom.Johnson@PGXLab.com